Thrombosis and Haemostasis 2024 Editors' Choice Papers

Publikationsverlauf

Eingereicht: 02. Dezember 2024

Angenommen: 02. Dezember 2024

Artikel online veröffentlicht:
03. Januar 2025

• References

• 1 Potpara T, Romiti GF, Sohns C. The 2024 European Society of Cardiology guidelines for diagnosis and management of atrial fibrillation: a viewpoint from a practicing clinician's perspective. Thromb Haemost 2024; 124 (12) 1087-1094
• 2 Treewaree S, Lip GYH, Krittayaphong R. Non-vitamin K antagonist oral anticoagulant, warfarin, and ABC pathway adherence on hierarchical outcomes: Win Ratio analysis of the COOL-AF registry. Thromb Haemost 2024; 124 (01) 69-79
• 3 Teppo K, Lip GYH, Airaksinen KEJ. et al. Comparing CHA₂DS₂-VA and CHA₂DS₂-VASc scores for stroke risk stratification in patients with atrial fibrillation: a temporal trends analysis from the retrospective Finnish AntiCoagulation in Atrial Fibrillation (FinACAF) cohort. Lancet Reg Health Eur 2024; 43: 100967
• 4 Teppo K, Airaksinen KEJ, Jaakkola J. et al. Ischaemic stroke in women with atrial fibrillation: temporal trends and clinical implications. Eur Heart J 2024; 45 (20) 1819-1827
• 5 Corica B, Lobban T, True Hills M, Proietti M, Romiti GF. Sex as a risk factor for atrial fibrillation-related stroke. Thromb Haemost 2024; 124 (04) 281-285
• 6 Wang Y, Guo Y, Qin M. et al; Expert Reviewers. 2024 Chinese Expert Consensus Guidelines on the diagnosis and treatment of atrial fibrillation in the elderly, endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): executive summary. Thromb Haemost 2024; 124 (10) 897-911
• 7 Galliazzo S, Bucciarelli P, Barcellona D. et al. Practical suggestions for an optimal management of vitamin K antagonists: Italian Federation of Centers for the Diagnosis of Thrombotic Disorders and the Surveillance of the Antithrombotic Therapies (FCSA) position paper. Thromb Haemost 2024; 124 (08) 803-809
• 8 Bejjani A, Bikdeli B. Direct oral anticoagulants: quick primer on when to use and when to avoid. Thromb Haemost 2024
• 9 Mackay GA, Gall C, Jampana R, Sleith C, Lip GYH. SIGN Dementia Guideline Development Group. Scottish Intercollegiate Guidelines Network guidance on dementia: the investigation of suspected dementia (SIGN 168) with focus on biomarkers—executive summary. Thromb Haemost 2024; (e-pub ahead of print).
• 10 Yamashita T, Igawa Y, Fukuzawa M, Hayashi T, Hennig S, Okumura K. Pharmacokinetics of edoxaban 15 mg in very elderly patients with nonvalvular atrial fibrillation: a subanalysis of the ELDERCARE-AF study. Thromb Haemost 2024; 124 (09) 874-882
• 11 Herron GC, DeCamillo D, Kong X. et al. Timing of off-label dosing of direct oral anticoagulants in three large health systems. Thromb Haemost 2024; (e-pub ahead of print).
• 12 Poli D. Off-label dosing of direct oral anticoagulants: prescribing error or opportunity in treating patients with atrial fibrillation?. Thromb Haemost 2024; (e-pub ahead of print).
• 13 Dix C, Doyle AJ, Breen K, Hunt BJ. The efficacy and safety of DOACs in inherited antithrombin deficiency: a cohort study from a tertiary referral center. Thromb Haemost 2024; (e-pub ahead of print).
• 14 Harenberg J, Gosselin RC, Cuker A. et al. Algorithm for rapid exclusion of clinically relevant plasma levels of direct oral anticoagulants in patients using the DOAC Dipstick: an expert consensus paper. Thromb Haemost 2024; 124 (08) 770-777
• 15 Weber C, Rigby A, Lip GYH. Thrombosis and Haemostasis 2023 Editors' Choice Papers. Thromb Haemost 2024; 124 (01) 80-87
• 16 Af S, Collaborators A-E. AF SCREEN and AFFECT-EU Collaborators. Protocol for a systematic review and individual participant data meta-analysis of randomized trials of screening for atrial fibrillation to prevent stroke. Thromb Haemost 2023; 123 (03) 366-376
• 17 Chao TF, Yeh YH, Chan YH. et al. The report of community-based and government-endorsed screening program of atrial fibrillation in Taiwan. Thromb Haemost 2024; 124 (01) 61-68
• 18 Romiti GF, Guo Y, Corica B, Proietti M, Zhang H, Lip GYH. mAF-App II trial investigators. Mobile health-technology-integrated care for atrial fibrillation: a Win Ratio analysis from the mAFA-II randomized clinical trial. Thromb Haemost 2023; 123 (11) 1042-1048
• 19 Danilatou V, Dimopoulos D, Kostoulas T, Douketis J. Machine learning-based predictive models for patients with venous thromboembolism: a systematic review. Thromb Haemost 2024; 124 (11) 1040-1052
• 20 Ortega-Martorell S, Olier I, Ohlsson M, Lip GYH. TARGET Consortium. TARGET: a major European project aiming to advance the personalised management of atrial fibrillation-related stroke via the development of health virtual twins technology and artificial intelligence. Thromb Haemost 2024; (e-pub ahead of print).
• 21 Liang B, Zha L, Peng B. et al. Association of cardiovascular health with the incidence of venous thromboembolism: a prospective study of 275,149 participants from the UK Biobank. Thromb Haemost 2024; 124 (10) 948-957
• 22 Lloyd-Jones DM, Allen NB, Anderson CAM. et al; American Heart Association. Life's Essential 8: updating and enhancing the American Heart Association's construct of cardiovascular health: a presidential advisory from the American Heart Association. Circulation 2022; 146 (05) e18-e43
• 23 Konstantinides SV. Shifting priorities in the prevention of venous thromboembolism: time to focus on overall cardiovascular health. Thromb Haemost 2024; 124 (10) 958-961
• 24 Du H-C, Deng B-Y. Obesity-related traits mediate the effects of educational attainment on the risk of varicose veins, venous thromboembolism, and phlebitis. Thromb Haemost 2024; 124 (10) 962-970
• 25 Pastori D, Sciacqua A. Educational attainment, obesity, and venous thromboembolism. Is only matter of weight?. Thromb Haemost 2024; 124 (10) 971-972
• 26 Wang Y, Hu X, Wang X, Li L, Lou P, Liu Z. Exploring the two-way link between migraines and venous thromboembolism: a bidirectional two-sample Mendelian randomization study. Thromb Haemost 2024; 124 (11) 1053-1060
• 27 Cohen AT, Creeper KJ, Alikhan R. et al. Early time courses of recurrent venous thromboembolism and bleeding during apixaban or dalteparin therapy for patients with cancer. Thromb Haemost 2024; 124 (07) 676-683
• 28 Sueta D, Yamashita Y, Morimoto T. et al; COMMAND VTE Registry-2 Investigators. Edoxaban, rivaroxaban, or apixaban for cancer-associated venous thromboembolism in the real world: insights from the COMMAND VTE Registry-2. Thromb Haemost 2024; 124 (11) 1013-1023
• 29 Pastori D, Palareti G. Open issues in the choice and management of direct oral anticoagulants in patients with cancer-related venous thromboembolism. Thromb Haemost 2024; 124 (11) 1024-1026
• 30 Cohen AT, Wallenhorst C, Rivera M. et al. Comparison of clinical outcomes in patients with active cancer receiving rivaroxaban or low-molecular-weight heparin: the OSCAR-UK study. Thromb Haemost 2024; (e-pub ahead of print).
• 31 Steiner D, Horváth-Puhó E, Jørgensen H, Laugesen K, Ay C, Sørensen HT. Risk of depression after venous thromboembolism in patients with hematological cancer: a population-based cohort study. Thromb Haemost 2024; (e-pub ahead of print).
• 32 Liu Y, Li D, Yu D. et al. Comprehensive analysis of hemophilia A (CAHEA): towards full characterization of the F8 gene variants by long-read sequencing. Thromb Haemost 2023; 123 (12) 1151-1164
• 33 Castaman G, Peyvandi F, Kremer Hovinga JA. et al. Surgical experience from the STASEY study of emicizumab prophylaxis in people with hemophilia A with factor VIII inhibitors. TH Open 2024; 8 (01) e42-e54
• 34 Jiménez-Yuste V, Álvarez-Román MT, Berrueco R. et al. Management of urgent bleeding in patients with hemophilia A: focus on the use of emicizumab. TH Open 2024; 8 (02) e194-e201
• 35 Chowdary P, Ofori-Asenso R, Nissen F. et al. Disease burden, clinical outcomes, and quality of life in people with hemophilia A without inhibitors in Europe: analyses from CHESS II/CHESS PAEDs. TH Open 2024; 8 (02) e181-e193
• 36 Lemons R, Wang M, Curtin J. et al. Safety and efficacy of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously untreated patients with hemophilia B. TH Open 2024; 8 (01) e155-e163
• 37 Kongebro EK, Diederichsen SZ, Xing LY. et al. Anticoagulation-associated bleeding in patients screened for atrial fibrillation versus usual care—a post hoc analysis from the LOOP study. TH Open 2024; 8 (01) e19-e30
• 38 Winijkul A, Kaewkumdee P, Yindeengam A, Lip GYH, Krittayaphong R. Clinical outcomes of patients with atrial fibrillation who survived from bleeding event: the results from COOL-AF Thailand registry. Thromb Haemost 2024; 124 (11) 991-1002
• 39 Kang DS, Yang PS, Kim D. et al. Racial differences in ischemic and hemorrhagic stroke: an ecological epidemiological study. Thromb Haemost 2024; 124 (09) 883-892
• 40 Kang DS, Yang PS, Kim D. et al. Racial differences in bleeding risk: an ecological epidemiological study comparing Korea and United Kingdom subjects. Thromb Haemost 2024; 124 (09) 842-851
• 41 Zheng Y, Li S, Liu X, Lip GYH, Guo L, Zhu W. Effect of oral anticoagulants in atrial fibrillation patients with polypharmacy: a meta-analysis. Thromb Haemost 2023; (e-pub ahead of print).
• 42 Grymonprez M, Petrovic M, De Backer TL, Steurbaut S, Lahousse L. The impact of polypharmacy on the effectiveness and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Thromb Haemost 2024; 124 (02) 135-148
• 43 Corica B, Romiti GF, Proietti M. NOACs in atrial fibrillation patients with polypharmacy. Thromb Haemost 2024; 124 (02) 149-151
• 44 Zhao F, Ding J, Cui J, Zhu M, Zhao W. Platelet activation is upregulated in cirrhotic patients with portal vein thrombosis. Thromb Haemost 2024; 124 (08) 739-752
• 45 Babickova J, Kałucka U, Sochaj-Grzegorczyk A. et al. Carbamylation is instrumental in end-stage kidney disease coagulopathies: the impact on von Willebrand factor and platelet functionality. Thromb Haemost 2024; (e-pub ahead of print).
• 46 Koenen RR. Carbamylation—a pathologic posttranslational modification affecting platelet and von Willebrand factor function during uremic kidney disease. Thromb Haemost 2024; (e-pub ahead of print).
• 47 Roka-Moiia Y, Lewis S, Cleveland E, Italiano JE, Slepian ML. Shear stress promotes remodeling of platelet glycosylation via upregulation of platelet glycosidase activity: one more thing. Thromb Haemost 2024; (e-pub ahead of print).
• 48 Braun A, Mammadova-Bach E. The hidden culprit: troubles with enhanced deglycosylation in mechanical circulatory support. Thromb Haemost 2024; (e-pub ahead of print).
• 49 Ueki Y, Häner JD, Losdat S. et al. Effect of alirocumab added to high-intensity statin on platelet reactivity and noncoding RNAs in patients with AMI: a substudy of the PACMAN-AMI trial. Thromb Haemost 2024; 124 (06) 517-527
• 50 Ortega-Paz L, Franchi F, Angiolillo DJ. The lipid-platelet interplay: unraveling the effects of PCSK9 inhibition on platelet reactivity. Thromb Haemost 2024; 124 (06) 528-532
• 51 Kapteijn MY, Bakker N, Koekkoek JAF, Versteeg HH, Buijs JT. Venous thromboembolism in patients with glioblastoma: molecular mechanisms and clinical implications. Thromb Haemost 2024; (e-pub ahead of print).
• 52 Wu X, Li L, Lu Z. et al. Heterozygous prothrombin mutation-associated thrombophilia. Thromb Haemost 2024; (e-pub ahead of print).
• 53 Dubacher N, Sugiyama K, Smith JD. et al. Novel insights into the aortic mechanical properties of mice modeling hereditary aortic diseases. Thromb Haemost 2024; (e-pub ahead of print).
• 54 de Waard V. Sensitivity to aortic rupture in hereditary aortic diseases. Thromb Haemost 2024
• 55 Yada N, Zhang Q, Bignotti A, Ye Z, Zheng XL. ADAMTS13 or caplacizumab reduces the accumulation of neutrophil extracellular traps and thrombus in whole blood of COVID-19 patients under flow. Thromb Haemost 2024; 124 (08) 725-738
• 56 Li Z, Zeng M, Wu T. et al. Causal effects of COVID-19 on the risk of thrombosis: a two-sample Mendel randomization study. Thromb Haemost 2024; 124 (08) 709-720
• 57 Gorog DA, Patel B. Tissue factor pathway inhibitor and interleukin-1 receptor levels in COVID-19. Thromb Haemost 2024; 124 (08) 721-724
• 58 Chen X, Li J, Liu P. et al. Inflammasome-independent mechanism of NLRP3 is critical for platelet GPIb-IX function and thrombosis. Thromb Haemost 2024; 124 (12) 1095-1113
• 59 Pennings GJ. NLRP3: more than an inflammasome?. Thromb Haemost 2024; 124 (12) 1114-1116
• 60 Li B, Lu M, Wang H. et al. Macrophage ferroptosis promotes MMP2/9 overexpression induced by hemin in hemorrhagic plaque. Thromb Haemost 2024; 124 (06) 568-580
• 61 Musialek P, Rosenfield K, Siddiqui AH, Grunwald IQ. Carotid stenosis and stroke: medicines, stents, surgery—“wait-and-see” or protect?. Thromb Haemost 2024; 124 (09) 815-827